Page last updated: 2024-12-08

19-oxo-deoxycorticosterone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

19-oxo-deoxycorticosterone (19-oxo-DOC) is a synthetic steroid hormone that is structurally similar to the naturally occurring hormone deoxycorticosterone (DOC).

**Here's why it's important for research:**

* **Mechanism of action:** 19-oxo-DOC is a potent agonist of the mineralocorticoid receptor (MR), meaning it binds to and activates this receptor. The MR is involved in regulating blood pressure, electrolyte balance, and other physiological processes.
* **Studies of mineralocorticoid receptor function:** 19-oxo-DOC is used in research to study the function of the MR. It allows researchers to investigate the effects of MR activation in various systems and models, including in vitro cell culture experiments and in vivo animal studies.
* **Development of new drugs:** 19-oxo-DOC has been investigated as a potential therapeutic agent for conditions like Addison's disease, a disorder of adrenal insufficiency. It's also been studied as a potential treatment for congestive heart failure and other conditions where MR activation might be beneficial.

**However, there are also some limitations to its use:**

* **Side effects:** 19-oxo-DOC can cause significant side effects, including fluid retention, hypertension, and potassium depletion. These side effects limit its clinical use and necessitate careful monitoring.
* **Limited therapeutic window:** The therapeutic window for 19-oxo-DOC is narrow, meaning that the dose range between effectiveness and toxicity is small. This makes it challenging to find an optimal dose for individual patients.

**Overall, 19-oxo-DOC is a valuable tool for researchers studying the MR and its role in various physiological processes. While it has shown potential for therapeutic use, its side effects and narrow therapeutic window have hindered its clinical application.**

19-oxo-deoxycorticosterone: metabolite of deoxycorticosterone in rat adrenals [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID173380
CHEBI ID174650
SCHEMBL ID11102334
MeSH IDM0104106

Synonyms (10)

Synonym
CHEBI:174650
(8s,9s,10s,13s,14s,17s)-17-(2-hydroxyacetyl)-13-methyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthrene-10-carbaldehyde
75220-37-0
19-oxo-deoxycorticosterone
pregn-4-en-19-al, 21-hydroxy-3,20-dioxo-
21-hydroxy-4-pregnen-3,19,20-trione
SCHEMBL11102334
(2s,14s,15s)-14-(2-hydroxyacetyl)-15-methyl-5-oxotetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-ene-2-carbaldehyde
DTXSID50996681
21-hydroxy-3,20-dioxopregn-4-en-19-al
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
21-hydroxy steroid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (85.71)18.7374
1990's1 (14.29)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.21

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.21 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.29 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.21)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]